论文部分内容阅读
在健康受试者及心脏病人身上,异搏定使地高辛的稳态血药浓度增高60～80%。这一观察结果符合近来的报道:在单剂量药物动力学研究中,发现异搏定可降低地高辛的肾清除率以及代谢清除率。为了研究此一相互作用对临床毒性反应的影响,作者对8名健康受试者反复测定了联合用药前及用药过程中的地高辛动力学和红细胞内钠离子浓度。结果异搏定使地高辛的平均整体清除率由4.68±0.41减少为3.29±0.26ml/min/kg;生物半衰期由33.5±2.4h延长到41.4±±2.3h。通过对照可以看出,药物动力学上的这些改变是与细胞内钠离子浓度的升高同步的。由于人们早
In healthy subjects and heart patients, verapamil increases digoxin steady-state plasma concentrations of 60-80%. This observation is in line with recent reports: In a single-dose pharmacokinetic study, verapamil was found to reduce digoxin renal clearance and metabolic clearance. To investigate the effect of this interaction on clinical toxicity, the authors repeated the determination of digoxin kinetics and erythrocyte sodium concentration in eight healthy subjects before and during the combination regimen. Results Verapamil decreased the average clearance rate of digoxin from 4.68 ± 0.41 to 3.29 ± 0.26ml / min / kg. The biological half-life increased from 33.5 ± 2.4h to 41.4 ± 2.3h. As can be seen by comparison, these changes in pharmacokinetics are synchronized with an increase in intracellular sodium concentration. Because people are early